Vascepa® – USA

Vascepa® – USA

On Sep. 03, 2020, Federal Circuit affirmed (Rule-36 judgment) Nevada district court decision finding method of treating hypertriglyceridemia patents invalid as obvious.

This appeal was filed by Amarin (Plaintiff) against the decision of Nevada district court which held claims of US 8,293,728; US 8,318,715; US 8,357,677; US 8,367,652; US 8,431,560 and US 8,518,929 invalid in Hatch-Waxman litigation. District court found that defendants (Hikma & DRL) established by clear and convincing evidence at trial that all asserted claims are prima facie obvious. You can read the district court decision summary “reported here” on this blog.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved